Key facts
- · Type: New offering first sale 2026-04-23 · Amount sold: $0 · Total offering: $5M · SEC filing
- · Type: New offering first sale 2025-01-17 · Amount sold: $0 · Total offering: $31.98M · SEC filing
- · Type: New offering first sale 2024-04-15 · Amount sold: $5M · Total offering: $13.25M · SEC filing
- · Type: New offering first sale 2024-03-18 · Amount sold: $60M · Total offering: $159M · SEC filing
- · Type: New offering first sale 2022-12-28 · Amount sold: $1.03M · Total offering: $1.03M · SEC filing
ISELIN, NEW JERSEY
Biotechnology
6
$97.85M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-05-07 | New offering first sale 2026-04-23 | $0 | $5M | details · SEC filing |
| 2025-01-27 | New offering first sale 2025-01-17 | $0 | $31.98M | SEC filing |
| 2024-04-16 | New offering first sale 2024-04-15 | $5M | $13.25M | SEC filing |
| 2024-03-29 | New offering first sale 2024-03-18 | $60M | $159M | SEC filing |
| 2023-01-06 | New offering first sale 2022-12-28 | $1.03M | $1.03M | SEC filing |
| 2023-01-06 | New offering first sale 2022-12-28 | $31.82M | $31.82M | SEC filing |
Want the whole picture on Outlook Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Outlook Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Outlook Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Outlook Therapeutics, Inc.'s own filings with the SEC. The people those filings name are on the team page.